findmyKOL
Clinical trialNCT02661035CompletedPhase 2Interventional

Allo HSCT Using RIC for Hematological Diseases

SponsorMasonic Cancer Center, University of MinnesotaEnrollment156Acute Lymphocytic LeukemiaAcute Myelogenous LeukemiaB-Cell LymphomaBurkitt's LymphomaChronic Lymphocytic LeukemiaChronic Myelogenous Leukemia+12 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion. The primary objective is to evaluate rates of acute graft-versus-host disease (GVHD) grades II-IV and chronic GVHD with an updated GVHD prophylaxis of tacrolimus and mycophenolate mofetil (MMF) with a non-myeloablative preparative regimen in persons with hematologic malignancies.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Masonic Cancer Center at University of Minnesota

    Minneapolis, Minnesota, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ATG →Allopurinol →Cyclophosphamide →Fludarabine →Monomethyl fumarate →Peripheral Blood Stem CellsRelated or Unrelated Bone Marrow CellsTacrolimus →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
9 Mar 2017
Primary completion
17 Apr 2023
Completion
29 May 2023
Last update posted
21 Sept 2023
Registered enrollment
156
Registry id
NCT02661035
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.